However, a phase 2 study conducted in patients with IPF demonstrated that treatment of IPF with carlumab, an immunoglobulin G1κ monoclonal antibody that specifically binds to and neutralizes human CCL2, failed to provide benefit to patients with progressive disease [45]. Here, CCL2 is linked to idiopathic interstitial pneumonia.